The shares were sold in multiple transactions with prices ranging from $90.6202 to $90.6538. The total value of the transaction amounted to approximately $121,105. Following this sale, Woodworth holds 2,957 shares of Boston Scientific (NYSE:BSX), a prominent healthcare equipment company with a market capitalization of $133 billion. For deeper insights into BSX's valuation and 17 additional key ProTips, visit InvestingPro to access the comprehensive Pro Research Report. The shares were sold in multiple transactions with prices ranging from $90.6202 to $90.6538. The total value of the transaction amounted to approximately $121,105. Following this sale, Woodworth holds 2,957 shares of Boston Scientific, a prominent healthcare equipment company with a market capitalization of $133 billion. For deeper insights into BSX's valuation and 17 additional key ProTips, visit InvestingPro to access the comprehensive Pro Research Report.
In other recent news, Boston Scientific has been making strategic moves in the medical device sector, with significant acquisitions and progress in clinical trials. The company recently completed its acquisition of Axonics, a move aimed at bolstering its Urology and Pelvic Health business. This acquisition is expected to have a neutral impact on the company's adjusted earnings per share (EPS) for 2024 and 2025, with positive contributions anticipated in subsequent years.
Boston Scientific also announced a definitive agreement to acquire Intera Oncology Inc., a specialist in liver cancer treatment devices and medication. The acquisition, expected to conclude in the first half of 2025, aims to enhance Boston Scientific's interventional oncology portfolio.
The company's stock maintains its Hold rating by a prominent financial firm. Furthermore, Boston Scientific has approved its 2025 Annual Bonus Plan and adopted two new performance share programs.
The company has also resumed its AVANT GUARD clinical trial, focusing on a new treatment option for patients with persistent atrial fibrillation. Additionally, Boston Scientific plans to acquire Cortex, a private firm with a unique cardiac mapping system, a move positively received by analysts at TD Cowen.
Boston Scientific's cardiology business has reported robust growth rates, with a 27% increase in the U.S. and 18% internationally. The company is also investing in mitral and tricuspid therapies, aiming to double the global drug-coated balloon business by 2025. These are recent developments that reflect Boston Scientific's commitment to innovation and growth, particularly in the cardiology market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.